Elevated FBXO45 and metastatic HCC

Elevated FBXO45 expression has been identified as a critical driver of metastasis in hepatocellular carcinoma (HCC), particularly in cases involving TP53 mutations. Below is a detailed explanation of the relationship between elevated FBXO45 and metastatic HCC:

### 1. **FBXO45 Overview**

FBXO45 is an E3 ubiquitin ligase that plays a central role in protein ubiquitination, a process that tags proteins for various cellular fates, including degradation or stabilization. In the context of HCC, FBXO45 has been shown to act as an oncogenic driver, promoting cancer progression and metastasis.

### 2. **FBXO45 Expression in TP53-Mutated HCC**

• Elevated FBXO45 expression was observed in 78.3% of HCC patients with TP53 mutations, identifying an aggressive subtype of the disease.
• TP53 mutations activate the mTOR signaling pathway, which in turn increases FBXO45 expression. This establishes a direct link between TP53 loss and the metastatic potential of HCC via the mTOR–FBXO45 axis.

### 3. **Pro-Metastatic Role of FBXO45**

• **Enhanced Migration and Invasion:** FBXO45 overexpression significantly enhances the ability of HCC cells to migrate and invade, crucial steps in metastasis. Conversely, silencing FBXO45 suppresses these effects.
• **Lung Metastases in Mice:** Experimental models demonstrated that FBXO45 overexpression led to a sevenfold increase in lung metastases, confirming its pro-metastatic role in vivo.
• **EMT Induction:** FBXO45 promotes epithelial-to-mesenchymal transition (EMT), a process by which cancer cells acquire a more invasive and migratory phenotype. This is achieved by upregulating EMT markers such as N-cadherin, Snail, and vimentin, while downregulating E-cadherin.

### 4. **Mechanism of FBXO45-Driven Metastasis**

FBXO45 drives HCC metastasis through a unique molecular mechanism involving the stabilization of the Trk-fused gene (TFG) protein:

• **TFG Stabilization via Ubiquitination:** FBXO45 catalyzes K63-linked polyubiquitination at Lys103 (K103) of TFG. This noncanonical ubiquitination enhances TFG stability rather than targeting it for degradation.
• **TFG's Role in Oncogenic Pathways:** Stabilized TFG interacts with activating transcription factor 2 (ATF2), which activates NF-κB signaling. NF-κB, in turn, promotes EMT and metastasis.

### 5. **Key Pathways Activated by FBXO45**

• **ATF2–NF-κB Axis:** Stabilized TFG binds to ATF2, which upregulates NF-κB p65. This signaling cascade drives EMT and enhances the metastatic potential of HCC cells.
• **mTOR Signaling:** TP53 mutations activate mTOR, which induces FBXO45 expression, linking TP53 loss to metastatic behavior through the mTOR–FBXO45–TFG axis.

### 6. **Clinical Implications**

• **Correlation with Poor Prognosis:** High FBXO45 expression is positively correlated with TFG levels in clinical HCC samples (R = 0.52, p < 0.0001). Patients with co-overexpression of FBXO45 and TFG have significantly worse overall survival (p = 0.0015).
• **Metastasis Confirmation in Humans:** Both FBXO45 and TFG are more highly expressed in HCC patients with distant metastases compared to non-metastatic cases.
• **Independent of Proliferation:** Knockdown of TFG does not affect HCC cell proliferation but specifically inhibits FBXO45-induced migration and invasion, highlighting its metastasis-specific role.

### 7. **Therapeutic Potential**

• **Targeting the Signaling Axis:** The TP53–FBXO45–TFG–ATF2–NF-κB axis represents a promising therapeutic target for aggressive, TP53-mutant HCC.
• **Unique Mechanism of Action:** Unlike other E3 ubiquitin ligases, FBXO45 operates via the PAM–SKP1 complex instead of the typical Cullin1 scaffold, making it a distinct and potentially druggable target.

### 8. **Proposed Model of FBXO45-Driven Metastasis**

The study proposes the following model:

1. TP53 mutations activate mTOR signaling.

2. mTOR signaling induces FBXO45 expression.

3. FBXO45 stabilizes TFG via K103-linked ubiquitination.

4. Stabilized TFG binds ATF2, activating NF-κB p65.

5. NF-κB signaling promotes EMT, driving HCC metastasis, particularly to the lungs.

### Conclusion

Elevated FBXO45 expression is a key driver of metastasis in TP53-mutated HCC. By stabilizing TFG and activating the ATF2–NF-κB pathway, FBXO45 promotes EMT and enhances the metastatic potential of HCC cells. Its strong association with poor prognosis and its unique mechanism of action make FBXO45 a promising therapeutic target for aggressive HCC.